These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 11291746)

  • 1. Distribution of the methylpiperazinopyridobenzoxazepine derivative JL13, a potential antipsychotic, in rat brain.
    Guiso G; Caccia S
    J Pharm Pharmacol; 2001 Mar; 53(3):317-21. PubMed ID: 11291746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity, increases extracellular dopamine in the prefrontal cortex, but not in the striatum and the nucleus accumbens of rats.
    Invernizzi R; Garavaglia C; Samanin R
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Mar; 361(3):298-302. PubMed ID: 10731043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine and JL13 induce cross-tolerance to the clozapine discriminative stimulus in rats.
    Goudie AJ; Cole JC; Sumnall HR
    Behav Pharmacol; 2007 Feb; 18(1):9-17. PubMed ID: 17218793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JL13 has clozapine-like actions on thermoregulatory cutaneous blood flow in rats: Involvement of serotonin 5-HT1A and 5-HT2A receptor mechanisms.
    Capuano B; Crosby IT; McRobb FM; Taylor DA; Vom A; Blessing WW
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):136-42. PubMed ID: 19878703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity.
    Andrade YCP; Ropke J; Viana TG; Fanelli C; Minaldi E; Batista LA; Issy AC; Del Bel EA; Rodrigues LCM; Liégeois JF; Moreira FA
    Behav Pharmacol; 2021 Feb; 32(1):2-8. PubMed ID: 33399294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: a review of its behavioural properties.
    Bruhwyler J; Liégeois JF; Bergman J; Carey G; Goudie A; Taylor A; Meltzer H; Delarge J; Géczy J
    Pharmacol Res; 1997 Oct; 36(4):255-64. PubMed ID: 9425613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation.
    Liégeois JF; Deville M; Dilly S; Lamy C; Mangin F; Résimont M; Tarazi FI
    J Med Chem; 2012 Feb; 55(4):1572-82. PubMed ID: 22268448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tissue distribution of a new heterocyclic N-phenylpiperazine derivative (LASSBio-581) in rats.
    Tasso L; Neves G; Menegatti R; Fraga CA; Barreiro E; Eifler-Lima V; Rates SM; Costa TD
    Eur J Pharm Sci; 2005 Oct; 26(2):194-202. PubMed ID: 16076552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia.
    Ellenbroek BA; Liégeois JF; Bruhwyler J; Cools AR
    J Pharmacol Exp Ther; 2001 Jul; 298(1):386-91. PubMed ID: 11408566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: application to the pharmacokinetic study.
    Shimokawa Y; Akiyama H; Kashiyama E; Koga T; Miyamoto G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jul; 821(1):8-14. PubMed ID: 15897016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and tissue distribution of olanzapine in rats.
    Aravagiri M; Teper Y; Marder SR
    Biopharm Drug Dispos; 1999 Nov; 20(8):369-77. PubMed ID: 10870093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain uptake and distribution of the potential memory enhancer CL 275,838 and its main metabolites in rats: relationship between brain concentrations and in vitro potencies on neurotransmitter mechanisms.
    Caccia S; Confalonieri S; Guiso G; Bernasconi P; Cagnotto A; Skorupska M; Mennini T
    Psychopharmacology (Berl); 1994 Aug; 115(4):502-8. PubMed ID: 7871095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homology Modeling Inspired Synthesis of 5-HT2A Receptor Inhibitors: A Diazepine Analogue of the Atypical Antipsychotic JL13.
    Mongeau E; Yuan G; Minden Z; Waldron S; Booth R; Felsing D; Ondrechen MJ; Jones GB
    Cent Nerv Syst Agents Med Chem; 2017; 17(3):239-244. PubMed ID: 28462720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype.
    Conrado DJ; Verli H; Neves G; Fraga CA; Barreiro EJ; Rates SM; Dalla Costa T
    J Pharm Pharmacol; 2008 Jun; 60(6):699-707. PubMed ID: 18498705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
    Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
    J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats.
    Aravagiri M; Marder SR
    Psychopharmacology (Berl); 2002 Feb; 159(4):424-31. PubMed ID: 11823895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and brain uptake of AM-36, a novel neuroprotective agent, following intravenous administration to rats.
    Nicolazzo JA; Nguyen TT; Katneni K; Steuten JA; Smith G; Jarrott B; Callaway JK; Charman SA
    J Pharm Pharmacol; 2008 Feb; 60(2):171-8. PubMed ID: 18237464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution and metabolism of the antipsychotic agent mazapertine succinate in rats.
    Caldwell GW; Wu WN; McKown LA; Diane Gauthier A; Masucci JA; Jones WJ; Leo GC; Reitz AB
    J Pharm Biomed Anal; 2006 May; 41(2):500-9. PubMed ID: 16386397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment.
    Daniel WA; Syrek M; Mach A; Wójcikowski J; Boksa J
    Pol J Pharmacol; 1997; 49(6):439-52. PubMed ID: 9566048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPLC detection of thioperamide from biological samples and its determination in rat blood and brain after systemic administration.
    Bordi F; Mor M; Plazzi PV; Silva C; Caretta A; Morini G
    Farmaco; 1992; 47(7-8):1095-103. PubMed ID: 1445616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.